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Sco1 is a metallochaperone that is required
for copper delivery to the CuA site in the
CoxII subunit of cytochrome c oxidase. The
only known missense mutation in human
Sco1, a P174L substitution in the copper-
binding domain, is associated with a fatal
neonatal hepatopathy; however, the
molecular basis for dysfunction of the protein
is unknown. Immortalized fibroblasts from a
SCO1 patient show a severe deficiency in
cytochrome c oxidase activity that is partially
rescued by overexpression of P174L Sco1.
The mutant protein retains the ability to bind
Cu(I) and Cu(II) normally when expressed in
bacteria, but Cox17-mediated copper transfer
is severely compromised both in vitro and in a
yeast cytoplasmic assay. The corresponding
P153L substitution in yeast Sco1 is impaired
in suppressing the phenotype of cells
harboring the weakly functional C57Y allele
of Cox17; however, it is functional in sco1Δ
yeast when the wild-type COX17 gene is
present. Pulse–chase labeling of
mitochondrial translation products in SCO1
patient fibroblasts showed no change in the
rate of CoxII translation, but a specific and
rapid turnover of CoxII protein in the chase.
These data indicate that the P174L mutation
attenuates a transient interaction with Cox17
that is necessary for copper transfer. They
further suggest that defective Cox17-
mediated copper metallation of Sco1, and
subsequent failure of CuA site maturation, is
the basis for the inefficient assembly of the
cytochrome c oxidase complex in SCO1
patients.
Cytochrome c oxidase (CcO) is the
terminal enzyme of the energy transducing
respiratory chain in mitochondria of eukaryotes
and in certain prokaryotes. The enzyme
catalyzes the reduction of molecular oxygen and
couples this reduction with proton translocation
across the inner membrane to generate the
membrane potential used to synthesize ATP.
The mammalian enzyme consists of 13 subunits,
three of which, CoxI, CoxII and CoxIII, are
mitochondrially-encoded and form the catalytic
core.  Structurally conserved domains within
subunits I and II contain the copper and heme
cofactors that are essential for the catalytic
competence of the holoenzyme (1). CoxI
contains two heme A moieties, one of which
interacts with a mononuclear copper site
forming a heterobimetallic site, designated heme
A3-CuB.  Two additional copper ions exist in a
cysteine-bridged, binuclear, mixed valent center
in CoxII designated CuA. Assembly of
individual structural subunits into a functional
holoenzyme complex within the mitochondrial
inner membrane requires over thirty accessory
factors (2).
Isolated CcO deficiency, one of the most
commonly recognized causes of respiratory
chain defects in humans, is associated with a
wide spectrum of clinical phenotypes (3,4), and
autosomal recessive mutations have been
identified in six nuclear genes that encode CcO
assembly factors in these patients,(3-9). Two
such factors, SCO1 and SCO2 encode
metallochaperones that  play a role in the copper
ion metallation of the CuA site in CoxII.  This
step in CcO assembly requires a single Sco
2protein in yeast (Sco1), but both Sco proteins are
essential in humans. Recent studies with
immortalized fibroblasts from SCO1 and SCO2
patients suggest that Sco1 and Sco2 have non-
overlapping but cooperative functions in the
maturation of the CuA site (10), although their
specific molecular roles in CcO assembly have
yet to be defined.
 Sco1 was first implicated in copper
delivery to CcO by the observation that the
respiratory deficient phenotype of a cox17-1
yeast mutant was suppressed by overexpression
of SCO1 (11). Deletion of the SCO1 gene in
yeast cells produces a respiratory phenotype
attributable to a lack of CcO activity. Structural
studies of Sco1 show that it has a globular
domain with a thioredoxin fold consisting of a
central four stranded β sheet covered with
flanking helices that protrude into the
mitochondrial intermembrane space (IMS) (12).
Two other notable features of Sco proteins are a
conserved pair of cysteinyl residues in a CxxxC
motif and a conserved histidyl residue. These
residues are spatially close in the apo-Sco1
structure in a solvent-exposed pocket (12).
Sco1 is capable of binding a single Cu(I)
ion (18). X-ray absorption spectroscopy suggests
that the Cu(I) is ligated via two sulfur donors
and a nitrogen. Mutation of either the Cys or His
residues abolishes Cu(I) binding and results in a
non-functional CcO complex (18). Cox17 is the
likely physiological copper donor to Sco1 (19)
consistent with the postulate that Sco1 mediates
Cu(I) transfer from Cox17 to CoxII. Sco
proteins also bind Cu(II) (13). The Cu(II) site
resembles a type II Cu(II) site with a higher
coordination number than the three-coordinate
Cu(I) site. A D238A substitution in yeast Sco1
abrogated Cu(II) coordination and led to a
nonfunctional protein. These data suggest that
both Cu(I) and Cu(II) binding are critical for
normal Sco1 function (13).
Mutations in either hSCO1 or hSCO2
result in pronounced CcO deficiency and lead to
different, early onset, fatal clinical phenotypes
(4,6,7,14). SCO2 mutations are associated with
neonatal encephalocardiomyopathy, whereas
SCO1 patients present with neonatal hepatic
failure and ketoacidotic coma. These distinct
clinical phenotypes are not a result of tissue-
specific expression of the two genes, as SCO1
and SCO2 are ubiquitously expressed and
exhibit a similar expression pattern in different
human tissues (4).  
All reported SCO2 patients carry an
E140K missense mutation on one allele, and are
either homozygous for this mutation or are
compound heterozygotes.  Homozygous patients
have a delayed onset of the disease pathology
and a more prolonged course of disease as
compared to heterozygotes (14). SCO1
mutations have only been identified in a single
pedigree in which the reported patients carried a
nonsense mutation on one allele and a P174L
missense mutation on the second allele (5). Both
the E140K and P174L substitutions are adjacent
to the CxxxC sequence motif.
Human Sco1 and Sco2 are
nonfunctional in yeast sco1Δ cells (15);
however, a chimeric protein consisting of 158
residues from the N-terminus of yeast Sco1
fused to a C-terminal segment of hSco1, but not
hSco2, is functional. A P174L substitution was
found to attenuate its function (15,16), although
the CcO deficiency in yeast sco1Δ cells
harboring the mutant yeast/human Sco1 chimera
could be rescued for growth on a
nonfermentable carbon by the addition of 0.2%
CuSO4 (16). This suggests that P174L Sco1
retains some residual function; however, the
molecular defect in Sco1 function that results
from this amino acid substitution remains
unknown. The present study was therefore
initiated to investigate whether copper binding is
defective in the P174L mutant Sco1. We report
that although copper binding is wild-type in the
mutant Sco1, its metallation by Cox17 is
severely compromised.
MATERIALS AND METHODS
Yeast strains and human cell lines-All yeast
strains used were in the W303 background
(MAT a, ade2–1, his3–1,15, leu2,3,112, trp1–1,
ura3–1). Cells were cultured with glucose,
raffinose, or galactose as carbon sources as
described (19). DNA transformations were
performed using a lithium acetate protocol.
 Primary cell lines from control SCO1
and SCO2 patient skin fibroblasts were
immortalized and cultured as previously
3described (10). Preparation and supplementation
of the growth media with copper histidine (Cu-
His) was also as described elsewhere (10).
Plasmids- The construction of YEp-GAL1-
hSCO1 and pHis-hSCO1 were described
previously (13).  The P174L mutation was
introduced into these plasmids using the
QuickChangeTM site-directed mutagenesis kit
(Stratagene, La Jolla, CA). A pRS413 vector
(YCp) expressing yeast SCO1 with a C-terminal
HA tag sequence under the control of the
MET25 promoter with a CYC1 terminator was
used as a template to generate the P153L
mutation. The entire insert was then subcloned
into a pRS423 vector (YEp). The MET25
promoter was also replaced with the 350
upstream base pairs that make up the natural
SCO1 promoter in the centromeric vector. The
plasmid encoding Cyb2-C57Y Cox17 was
described previously (17). DNA sequences were
confirmed prior to use.
Wild-type hSCO1 cloned into the
Gateway-modified retroviral expression vector
pLXSH was used as a template to generate the
P174L point mutant using the QuickChangeTM
mutagenesis. The fidelity of the resultant
construct was confirmed by sequencing. Phoenix
amphotropic cells (Dr. G. Nolan, Stanford
University) were used to transiently produce and
package all individual human cDNA constructs.
Subsequent infection and selection of fibroblast
cell lines were done  as previously described
(10).
Protein Purification-Recombinant human and
yeast Sco1 proteins were purified from BL21
(DE3) transformants harboring pHis-hSCO1
(His-tagged SCO1 or mutant SCO1) as described
previously (18). Yeast transformants with YEp-
GAL1-hSCO1 were cultured in raffinose
medium to an A600 nm of 0.6. Galactose was then
added to induce expression of the His-tagged
Sco1.  Cells were harvested after 5 h and lysates
were prepared by use of a French press. Nickel-
NTA Superflow (Qiagen) was used for the
purification of the His-tagged Sco1 proteins
from clarified samples.
Spectroscopic analyses - Absorption spectra
were recorded with a Beckman DU640
spectrophotometer. X-band EPR spectra were
obtained on a 9 GHz Bruker EMX spectrometer.
All samples were run at 77K in a liquid nitrogen
finger dewar. Spin quantitation was determined
relative to a 0.5 mM CuEDTA standard.
Luminescence was monitored on a Perkin Elmer
fluorimeter with excitation wavelength of 300
nm and emissions were scanned from 350 to 700
nm. Excitation slit of 5 nm and emission slit of
15 nm and a 350 nm bandpass filter were used.
The copper concentration of the protein samples
was measured using a Perkin Elmer  (AAnalyst
100) atomic absorption spectrophotometer or a
Perkin Elmer Optima (3100XL) ICP
spectrometer. Circular dichroism spectra were
recorded on an Aviv 62DS spectrometer at room
temperature using a 0.3 cm cuvette path length
and are the average of three scans.
Assays-A bathocuproine sulfonate (BCS) assay
was used to determine the Cu(I) content of the
protein samples. The appearance of a Cu(BCS)2
complex was measured by monitoring the
absorbance at 483 nm using a molar extinction
coefficient of 12,250 cm-1M-1. Protein was
quantified by amino acid analysis after
hydrolysis in 5.7 N HCl at 110 °C in vacuo on a
Beckman 6300 analyzer.
Mitochondrial translation studies-Cells were
pulse-labelled for 60 min at 37o C in
methionine-free DMEM containing 200 µCi/ml
[35S]methionine and anisomycin (100µg/ml) , a
reversible cytosolic translation inhibitor, and
chased for up to 17.5 hr in regular DMEM. Total
cellular protein (50 µg) was resuspended in
loading buffer containing 93 mM Tris-HCl, pH
6.7, 7.5% glycerol, 3.5% SDS, 0.25 mg
bromophenol blue/ml and 3% mercaptoethanol,
sonicated for 3–8 s, loaded and run on 12-20%
polyacrylamide gradient gels.
Immunoblot Analysis of yeast proteins-Protein
(10–50 µg) from the mitochondrial fraction was
electrophoresed on a 15% SDS-PAGE gel
system and transferred to nitrocellulose (Bio-
Rad Laboratories). Membranes were blocked in
1x phosphate-buffered saline (50 mM Na2PO4,
100 mM NaCl, pH 7.0), 0.01% Tween 20, and
10% milk solution prior to detection with
appropriate antibodies and visualization with
Pierce chemiluminescence reagents using a
horseradish peroxidase-conjugated secondary
antibody. Antiserum to porin (Por1) was from
Molecular Probes. Rabbit anti-Sco1 antiserum
was generated as described previously (18).
4Immunoblot analysis of human proteins-
Immortalized human fibroblasts and myoblasts
were differentially permeabilized using digitonin
in order to generate mitochondrially-enriched
fractions, and subsequently solubilized in
phosphate buffered saline containing 1.5%
lauryl maltoside supplemented with complete
protease inhibitor cocktail (Roche) (10). Equal
amounts of protein were fractionated on 12%
SDS-PAGE gels, and transferred to
nitrocellulose. Membranes were blotted with
polyclonal antisera raised against human Sco1
and CoxII, and a monoclonal anti-Por1 antibody
(Calbiochem). Following incubation with the
relevant secondary antibody, immunoreactive
proteins were detected by luminol-enhanced
chemiluminescence (Pierce).
Miscellaneous - Protein concentration, CcO and
citrate synthase activities in human cell lines
were measured as described elsewhere (10).
RESULTS
Immortalized fibroblasts from a SCO1
patient with the P174L substitution exhibit a
severe deficiency in CcO, which is reflected in
both low residual enzyme activity and low
steady-state levels of CoxII protein (Figs. 1A,C).
Transduction of patient fibroblasts with a
retroviral virus overexpressing SCO1 completely
restored wild-type CcO activity  (Fig. 1A) (10),
while over-expression of  the P174L mutant
SCO1 only partially rescued the CcO deficiency
(Fig. 1A). These changes in CcO activity were
accompanied by parallel increases in the steady-
state levels of CoxII protein  (Fig. 1C). Residual
CcO activity in P174L-overexpressing SCO1
patient fibroblasts could be further increased by
supplementing the growth media with Cu-His
(Fig. 1A), an effect that was not attributable to
altered levels of Sco1 protein (data not shown)
These data demonstrate that the P174L mutant
Sco1 retains sufficient residual function to allow
for some assembly of the CcO holoenzyme.
Although the reduced CcO activity in
SCO1 patient cells could be partly due to
reduced Sco1 protein levels (10) (Fig. 1C), the
inability of overexpressed P174L Sco1 mutant to
fully restore CcO activity  argues that some
aspect of its function is impaired.  We
previously showed that overexpression of either
Sco protein in the reciprocal patient background
exerts a dominant-negative effect on CcO
activity (10) that was dependent on the Cu(I)-
binding Cys residues in Sco1 (13). To evaluate
whether the P174L substitution affected this
genetic interaction between Sco1 and Sco2, we
overexpressed either the wild-type or the P174L
mutant Sco1 in SCO2 patient fibroblasts. Both
wild-type and mutant Sco1 proteins exerted a
comparable dominant-negative effect on residual
CcO activity and residual CoxII protein levels
(Fig. 1B,D). This phenotype was robust, and
could not be perturbed by the presence of Cu-
His in the growth media. These results suggest
that at least a fraction of over-expressed P174L
Sco1 is metallated in SCO2 fibroblasts.
To further evaluate the molecular defect
in the P174L mutant Sco1, N-terminal truncates
of wild-type and P174L human Sco1 were
expressed and purified (13) to characterize their
copper-binding properties. Both wild-type Sco1
and the P174L mutant protein eluted from gel
filtration in fractions corresponding to
monomeric molecules, and each contained 0.9
mol equiv. of copper (Table I). Dialysis of the
copper-containing proteins overnight in 1 mM
EDTA/1 mM DTT resulted in only a slight
depletion of bound copper; both wild-type and
P174L Sco1 proteins retained 0.8 mol equiv.
bound copper. The copper binding avidity to
wild-type and P174L Sco1 was therefore similar.
Titration of the proteins with varying levels of
the Cu(I) specific chelator bathocuproine
sulfonate (BCS) revealed a similar BCS
concentration dependency in Cu(I) depletion,
further suggesting that Cu(I) coordination was
similar in the two proteins (Fig. 2).
The Cu(II) content, assessed by the
quantity of copper that is not BCS-titratable, was
0.4 mol equiv. for both the wild-type and P174L
Sco1 (Table I). Absorption spectroscopy of
purified wild-type Sco1 revealed the expected
transitions of the Cu(II) chromophore in the
visible spectral region with maxima at 360 and
480 nm (Fig. 3A). The P174L Sco1 exhibited
the same transitions, confirming that the mutant
Sco1 binds Cu(II) in a manner analogous to that
of the wild-type protein. Comparable Cu(II)
coordination between wild-type and P174L Sco1
was further confirmed by electron paramagnetic
resonance spectroscopy;  both proteins exhibited
5similar hyperfine splittings of the gz component
of the Cu(II) signal (Fig. 3B). Far UV circular
dichroism revealed that the wild-type and
mutant Sco1 proteins exhibited similar bulk
structure, with comparable ellipticity in the two
proteins, suggesting that the P174L substitution
fails to grossly perturb the tertiary conformation
of the protein (Fig. 4). Collectively, these data
strongly suggest that the molecular defect
caused by the P174L substitution does not result
from aberrant copper binding.
We demonstrated previously that Cox17
is a Cu(I) donor to yeast and human Sco1 using
both in vitro and in vivo approaches (13,19). To
investigate whether P174L Sco1 can be
metallated by Cox17, purified wild-type and
mutant Sco1 proteins were initially tested in an
in vitro transfer assay. CuCox17 exhibits a
characteristic luminescence at 580 nm that, upon
addition of apo-Sco1, leads to an attenuation in
emission due to Cu(I) transfer (19). The addition
of apo-hSco1 to CuCox17 resulted in a rapid
attenuation in the Cox17 luminescence (Fig.
5A). Subsequent purification of hSco1 by Ni-
NTA chromatography and quantitation of bound
copper confirmed that quenching of Cox17
luminescence was attributable to copper transfer
(Fig. 5C). The eluate contained only hSco1, so
the observed copper transfer between Cox17 and
hSco1 was likely mediated by transient
interactions between the two proteins (Fig. 5D).
The specificity of the Cu(I) transfer from Cox17
to hSco1 was verified by using a C57Y mutant
Cox17 that we previously demonstrated fails to
transfer Cu(I) to yeast Sco1 (19). As before,
incubation of hSco1 with the yeast C57Y mutant
Cox17 failed to show any Cu(I) transfer, as
assessed by the lack of diminution in the Cox17
emission spectrum (Fig. 5A).
In contrast to wild-type hSco1,
incubation of CuCox17 with P174L hSco1 failed
to show either a diminution in CuCox17
emission or Cu(I) transfer after recovery of the
mutant protein (Fig. 5B,C).  Increasing the
concentration of CuCox17 five-fold in the
reaction resulted in limited transfer of Cu(I) to
the purified P174L hSco1 sample to a final
stoichiometry of 0.4 mol eq. (data not shown).
As expected, incubation of the yeast C57Y
mutant Cox17 and the P174L hSco1 failed to
show any Cu(I) transfer (Fig. 5B).
The inability of P174L hSco1 to be
metallated by CuCox17 was further confirmed
using the yeast cytosolic assay (19). Constructs
encoding the globular domains of hSco1 and
P174L hSco1 as His-tag fusions were expressed
from the GAL1 promoter on a high copy YEp
plasmid. The proteins accumulated in the yeast
cytoplasm as they lacked their usual
mitochondrial targeting sequence and
transmembrane domains. Purification of hSco1
from the cytoplasm of cells co-expressing
Cox17 and cultured in synthetic complete
medium resulted in recovery of hSco1 with a
bound copper content of 0.9 mol equiv. (Fig. 6).
In contrast, co-expression of Cox17 and P174L
hSco1 yielded only residual copper (0.1 mol
equiv.) in the purified mutant Sco1, consistent
with the above in vitro data.
 The failure of Cox17 to metallate P174L
Sco1 may in part explain the very low steady-
state levels of CoxII protein observed in SCO1
patient fibroblasts (Fig. 1C). To evaluate the
effects of the P174L substitution on CoxII
expression at the protein level, pulse-chase
labeling experiments of mitochondrial
translation products were conducted.  Rates of
CoxII protein synthesis were comparable in
control and SCO1 patient fibroblasts; however,
there was a dramatic reduction in the stability of
nascent CoxII in SCO1 patient fibroblasts during
the chase  (Fig. 7A). The temporal loss of CoxII
preceded similar reductions in the levels of CoxI
and CoxIII, the two other mitochondrially-
encoded structural subunits (Fig. 7B).
Radiolabelled CoxII was undetectable eight
hours post-chase in SCO1 patient fibroblasts
(Fig. 7B). In contrast, roughly 20% of the total
radiolabelled CoxII pool from the pulse
remained in control fibroblasts, an amount that
persisted until the final time point at 17.5h (Fig.
7B).
Pro174 is a conserved residue in
eukaryotic Sco proteins. To determine whether a
corresponding mutation in yeast SCO1
attenuated function, a P153L substitution was
engineered in yeast SCO1 and expressed on a
centromere-based vector from its natural
promoter. Yeast cells lacking Sco1 are
respiratory deficient and lack CcO activity.
Transformation of sco1∆ cells with a mutant
SCO1 encoding the P153L substitution
6suppressed the growth phenotype of sco1∆ cells
on ethanol/glycerol (Fig. 8) and restored wild-
type oxygen consumption, suggesting that the
P153L mutant protein was functional. As a
second test of functionality, we evaluated the
ability of mutant SCO1 to suppress the
respiratory deficiency of cox17-1 cells. This
partially functional allele of Cox17 contains a
C57Y substitution, and glycerol growth of
cox17-1 cells can be restored by overexpression
of SCO1 (11). To test for potential suppression
by mutant Sco1, we used cox17Δ cells harboring
a plasmid expressing C57Y Cox17 as a fusion
protein with the Cyb2 heme domain (designated
Cox17-1*) to allow for its efficient
accumulation within the IMS. Mutant cox17-1
cells with either wild-type or the P153L mutant
SCO1 were plated on glycerol-containing
medium. Whereas wild-type SCO1 reversed the
growth phenotype on glycerol/ethanol when
expressed from a YCp plasmid under its natural
promoter (Fig. 9A), complementation of the
phenotype by the P153L Sco1 required a much
higher level of expression of the protein (Fig.
9A). Western analysis revealed that the wild-
type and mutant protein accumulated to similar
extents (Fig. 9B), ruling out the possibility that
the inactivity of P153L Sco1 arose from reduced
levels of the mutant protein.
The ability of Sco1 to restore glycerol
growth of cox17Δ cells was dependent on the
presence of C57Y Cox17. In the absence of
C57Y Cox17, suppression of cox17Δ cells
requires SCO1 overexpression and the addition
of exogenous copper to the growth medium.
Partial suppression of cox17Δ cells by
overexpression of P153L Sco1 occurred in the
presence of exogenous copper added to the
growth medium (Fig. 9A).
DISCUSSION
The present study clearly demonstrates
that the P174L substitution in hSco1 does not
affect the ability of the protein to bind and retain
Cu(I) or Cu(II), but rather impairs its ability to
receive copper from the metallochaperone
Cox17. Although the P174L variant has wild-
type copper-binding properties, its function in
vivo is severely compromised as evidenced by
the pronounced CcO assembly defect in SCO1
patient tissues and fibroblasts (6,10).
Overexpression of the mutant SCO1 in patient
fibroblasts only partially suppresses the CcO
deficiency, consistent with a loss of function
mutation. 
Using in vitro and in vivo copper
transfer assays we previously showed that
Cox17 transfers Cu(I) to both Sco1 and Cox11
in yeast (19), and that  hCox17  transfers Cu(I)
to hSco1 (13). The specificity of this transfer
reaction is highlighted by a mutant form of
Cox17 (C57Y) that fails to transfer Cu(I) to
Sco1 despite normal Cu(I) binding and transfer
to Cox11. The P174L substitution in Sco1 also
appears to perturb the interaction with Cox17, as
its metallation in both the in vitro assay and the
in vivo yeast cytosolic assay was at residual
levels.
The failure of Cox17 to metallate P174L
hSco1 in vitro could be partially reversed by
substantially increasing Cox17 concentrations in
the transfer reaction, suggesting that
overexpression of either P174L Sco1 or hCox17
might rescue CcO activity in SCO1 patient
fibroblasts. Although we demonstrated partial
rescue of the CcO phenotype by overexpressing
P174L Sco1, we did not observe any rescue by
overexpressing Cox17, even though immunoblot
analysis of whole cell extracts indicated that we
were able to overexpress it 2-3 fold using
retroviral expression vectors (data not shown).
Cox17 is, however, distributed between the
cytoplasm and the mitochondrial IMS (20), and
it is possible that this experiment did not result
in a significant enough increase of Cox17
concentration in this compartment to promote
copper loading of Sco1 in patient cells.
An attenuation of the interaction
between Cox17 and the mutant hSco1is further
supported by the observation that P153L Sco1 in
yeast is impaired in suppressing the phenotype
of cox17-1 cells harboring the C57Y substitution
in Cox17. Whereas overexpression of wild-type
Sco1 suppresses the growth phenotype of cox17-
1 cells on ethanol/glycerol, expression of P153L
SCO1 from a YCp vector fails to restore CcO
activity. Interestingly, the P153L substitution in
yeast Sco1 does not apparently compromise the
interaction with Cox17 as seriously as the P174L
mutation in the human protein. No respiratory
7phenotype is observed in sco1Δ cells expressing
the P153L Sco1.
The exact nature of the Cox17-Sco1
interaction is not yet clear. We have failed to
observe an interaction using affinity purification
of Sco1 from both in vivo and in vitro copper
transfer assays (19), suggesting that Cox17
donates Cu(I) through ligand exchange reactions
in a transient protein-protein interaction. We
propose that this complex is attenuated by the
C57Y substitution in Cox17 and by the P174L
substitution in Sco1. This could arise if Pro174
is part of the interaction interface, or
alternatively, if P174L alters Sco1 conformation.
It is conceivable that Sco1 exists in two
subconformational states, an open conformer
receptive to Cu(I) binding and a closed state
poised for transfer to CoxII. The failure of
Cox17 to donate Cu(I) to P174L Sco1 could
arise if Sco1 existed in the closed conformer,
mimicking the Cu-loaded state.
We cannot rule out the possibility that
the P174L substitution impairs copper transfer
from Sco1 to CoxII: however, the fact that the
CcO deficiency in SCO1 patient fibroblasts is
partially reversed by the addition of exogenous
copper salts to the culture medium (10) suggests
that it is more likely a copper loading problem.
Although the exact mechanism of copper
suppression of the mutant hSco1 remains
unresolved, the exogenous copper could bypass
Cox17 in the metallation of Sco1 within the IMS
using another metallochaperone. There are at
least two candidates that might be able to fulfill
this role, Cox19 and Cox23, both of which share
the conserved Cx9C motif originally identified in
Cox17 (21).
The most important ramification of the
P174L mutation in Sco1 is the failure to
incorporate newly synthesized CoxII into the
holoenzyme complex. This stalls the CcO
assembly process, resulting in accumulation of a
subassembly and the production of a limited
amount of active holoenzyme (22) .
Mitochondria contain a AAA protease system in
the inner membrane that is responsible for the
quality control of inner membrane proteins (23),
rapidly turning over newly synthesized
mitochondrial proteins that are not incorporated
into nascent enzyme complexes. While it is
therefore not surprising to find that nascent
mitochondrially-encoded Cox subunits are
degraded more rapidly in cells with a CcO
assembly defect than in controls, SCO1 patient
cells are unique in that the turnover of newly
synthesized CoxII occurs more rapidly than that
of CoxI and CoxIII. We have not observed this
specificity in other cell lines from patients with
other isolated CcO assembly defects and
similarly low residual CcO activity (unpublished
observations).  This suggests that it is the
inefficient maturation of the CuA site that results
in the disproportionately rapid degradation of
apo-CoxII molecules, further emphasizing that
CoxII is the molecular target of Sco1.
Overexpression of P174L Sco1 as well
as wild-type hSco1 exerts a dominant negative
effect on CcO activity in SCO2 patient
fibroblasts, an effect that we previously showed
depends on intact copper binding in the wild-
type protein (13).  Mutant Sco1 must be at least
partly copper-loaded as it retains limited
function. It is possible that even a small pool of
metallated Sco1 would be sufficient to cause the
dominant negative effect in SCO2 patient cells,
as these cells have very low steady-state levels
of Sco2 protein. Alternatively, the P174L
substitution could stabilize a conformation
mimicking the copper-loaded state. Future
studies will address the effect of the P174L
substitution on the conformation of Sco1 and its
interaction with Sco2.
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9Total Cu/protein
   mol equiv.
  Cu(II)/protein
   mol equiv.
  Post-dialysis
Total Cu/protein
    mol equiv.
Post-dialysis
Cu(II)/protein
   mol equiv.
hSco1 0.94 + 0.1 0.40 + 0.05   0.80 + 0.1  0.40 + 0.07
hSco1
P174L
0.95 + 0.1 0.44 + 0.05   0.78 + 0.2  0.42 + 0.05
Table I
Cu(I) and Cu(II) binding stoichiometry of human Sco1 and Sco1 P174L
Protein samples were quantified for total copper by ICP-OES analysis. The Cu(II) content was
calculated by subtracting the BCS reactive Cu(I) (incubation with 25 mM BCS  for 30 min)
from the total copper amount and confirmed by quantitation of the Cu(II) EPR signal. Protein
was quantified by amino acid analysis. (n=3)
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Figure legends
Figure 1. Complementation analysis in SCO1 and SCO2 patient cell lines transduced with retroviral
expression vectors expressing either wild-type SCO1 or P174L SCO1. A,B) CcO activity, expressed as
a percentage of control (n=3-11), in untransduced SCO1 and SCO2 patient fibroblasts (baseline) and in
cells overexpressing either wild-type or P174L Sco1. Baseline and retroviral-overexpressing cells were
grown in either the absence or presence of 30µM copper-histidine (Cu-His) for 7 days prior to analysis.
C,D) Immunoblot analysis of expression of Sco1 and CoxII in control and patient fibroblast (panel C) and
myoblast (panel D) lines in untransduced cells (-) and in cells overexpressing either wild-type Sco1 or
P174L Sco1. Porin served as an internal loading control.
Figure 2. Competition of hSco1 and hSco1 P174L with the Cu(I)-chelator BCS. Cu(BCS)2 complex
was measured by monitoring the absorbance at 483 nm using a molar extinction coefficient of 12,250 cm-
1M-1. 20 µM of hSco1 (bold line) and hSco1 P174L (dashed line) were incubated with varying
concentrations of BCS and the Cu(BCS)2 complex was quantified after 10 min. Representative data are
shown of n=3.
Figure 3.  Spectroscopic characterization of the Cu(II) site in hSco1 and hSco1 P174L. A) Absorption
spectra of purified hSco1 (bold line) and hSco1 P174L (dashed line). B) EPR spectra of purified hSco1
(top) and hSco1 P174L (bottom) with each sample present at a final copper concentration of 0.5 mM. The
spectra were recorded at 77K at a power setting of 19.8 mW and a modulation amplitude of 4.0 G.
Representative data are shown of n=3.
Figure 4. Far UV circular dichroism spectra of purified hSco1 and hSco1 P174L. The concentrations
of purified hSco1 (bold line) and hSco1 P174L (dashed line) were 25 µM.
Figure 5. Cox17-mediated copper transfer to hSco1 and hSco1 P174L. CuCox17 or CuCox17-C57Y
present at 20 µM was incubated with 50 µM apo hSco1 or hSco1 P174L for the in vitro transfer reaction.
A) The luminescence of CuCox17 before (solid line, top panel) and after the addition of apo-hSco1
(dashed line, top panel) is shown. The bottom panel shows the luminescence of CuCox17-C57Y before
(solid line) and after the addition of apo-hSco1 (dashed line).  B) The luminescence of CuCox17 before
(solid line, top panel) and after the addition of apo-hSco1 P174L (dashed line, top panel) is shown. The
emission of CuCox17-C57Y before (solid line, bottom panel) and after the addition apo-hSco1 P174L
(dashed line, bottom panel) is shown. C) The copper content of His-tagged hSco1 and hSco1 P174L after
purification by Ni-NTA chromatography (eluate fractions) is shown by white bars (n=3). The unbound
fraction containing only Cox17 is shown by black bars D) SDS-PAGE of the eluate fractions containing
hSco1 and hSco1 P174L.
Figure 6. Copper transfer assay from Cox17 to hSco1 and hSco1 P174L in yeast cytoplasm. Yeast
cells containing plasmids expressing yeast Cox17 and the His-tagged soluble domains of either hSco1 or
hSco1 P174L were cultured as described in Material and Methods. The His-tag hSco1 proteins were
purified on Ni-NTA and the copper content of the eluted fractions are shown (n=3). The purity of the
hSco1 in the eluted fractions was determined by SDS-PAGE (inset).
Figure 7.  Synthesis and turnover of mitochondrial CcO subunits in SCO1 fibroblasts. A) Fibroblasts
from the SCO1 patient and a control were pulse-labeled for one hour with [35S]methionine in the presence
of a reversible inhibitor of cytoplasmic translation (anisomycin), followed by chase in regular medium for
various intervals of time (shown, in hours, at the top of the figure), to assess the rate of synthesis and the
stability of mitochondrial Cox subunits. Ten of the 13 mitochondrially-encoded structural subunits of the
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oxidative phosphorylation complexes are indicated at the left of the figure:  “CO”, subunits of CcO;
“ND”, subunits of complex I; cyt b, subunit of complex III; “ATP6”, subunit of complex V. B) The
temporal decrease of the three mitochondrially-encoded subunits of CcO in control patient fibroblasts is
expressed as percentage of radioactive counts incorporated following a 0.2 h chase period. The end points
of the experiment (0.2h pulse, 17.5 h chase were assessed in five independent experiments, while the
refined time course for the chase portion of the experiment was done singly.
Figure 8. Complementation of sco1∆ yeast cells growth defect on non-fermentable carbon sources
by ySco1 P153L. Serial dilutions of sco1∆ cells containing an empty plasmid (VEC) or a plasmid
expressing either SCO1 or SCO1 P153L under the control of the natural promoter were spotted onto
selective plates containing 2% glucose or 2% lactate - 2% glycerol with and without 1 mM CuSO4.
Figure 9. Suppression of cox17-1 cells by yeast Sco1 P153L. A) Transformants of cox17∆ cells were
spotted onto selective plates containing 2% glucose or 2% lactate - 2% glycerol with and without 1mM
CuSO4 as follows: empty plasmid (VEC), a plasmid encoding Cyb2-C57Y Cox17 (Cox17-1*) in
combination with YCp or YEp plasmids encoding either wild-type Sco1-HA (strip A) or Sco1-HA P153L
(strip B) under the control of the endogenous SCO1 (sco) or MET25 promoters (met). B) Immunoblot
analysis confirmed equal protein levels of Sco1-HA or Sco1-HA P153L in the cox17-1 cells.
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